New pill takes on tough cancers in first human test
NCT ID NCT06577987
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a first-in-human study, so the main focus is safety and tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CID-078 (an oral cyclin A/B-RxL inhibitor)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not yet proof of effectiveness. Many drugs fail at this stage, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Comprehensive Cancer Centers of Nevada
RECRUITINGLas Vegas, Nevada, 89169, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Mountain
RECRUITINGWest Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
UH Seidman Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States